Cure My Disease

Don't miss your cure!

 Log in / Sign up

New program aims to ease suffering for Alzheimer's patients in nursing homes

NCT ID NCT04520698

Symptom relief Sponsor: Indiana University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times

Summary

This study tested a program called UPLIFT-AD that brings palliative care—focused on comfort and quality of life—to nursing home residents with moderate to severe Alzheimer's disease. Over 1,300 residents, family members, and staff took part. The program included staff training, advance care planning, and access to palliative care specialists. The goal was to reduce symptoms like pain and agitation and improve satisfaction with care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
palliative care program (education, screening, care planning, consultations)
What this could lead to
If successful, this model could become a standard way to improve comfort and quality of life for people with advanced Alzheimer's in nursing homes.
What could go wrong
This is a completed study, but results may not apply to all nursing homes or residents. The intervention relies on staff training and resources, which may vary widely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

1,322 people

The number who actually took part.

Started

Sep 2021

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \- NURSING HOME RESIDENTS: * Long-stay resident in an enrolled nursing home defined as not paying through Medicare Part A at the enrolled facility. * Has a diagnosis of moderate to severe ADRD, as measured on the Minimum Data Set (MDS) * Length of stay \>30 days FAMILY MEMBERS/SURROGATE DECISION MAKERS: * Family member and/or surrogate decision maker for an eligible resident in an enrolled nursing home * English-speaking NURSING HOME STAFF: * Staff, nurse, or nurse assistant in an enrolled nursing facility * English-speaking Exclusion Criteria: \- NURSING HOME RESIDENTS: • Short-stay resident, defined as paying through Medicare Part A at the enrolled facility and/or receiving respite care FAMILY MEMBERS/SURROGATE DECISION MAKERS: • Non-English-speaking NURSING FACILITY STAFF: • Non-English-speaking

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer disease

Contacts and locations

Locations

  • American Senior Communities

    Indianapolis, Indiana, 46201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.